Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

The storytelling is brittle, but there is still enjoyment to be had from this story of a mother and child and rescue from a catastrophic flood in Seoul ...

Humans have a great capacity for both self-sabotage and unlimited learning. This makes us exceptionally unpredictable.

Meta’s AI organization underwent tremendous change in 2025. After the disappointing debut of its flagship Llama 4 model, ...

Viewed this way, a definition is a decision mechanism. It distinguishes some elements of the universe from the others. Hence ...